Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Seung-Hwan Lee, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2025-5149

Published: 2025

Journal Articles

Impact of pre-transplant cytoreductive therapy on post-transplant outcomes in patients with myelodysplastic syndromes with excess of blasts: A retrospective analysis

Yueun Lee, Je-Hwan Lee, Jung-Hee Lee, Yunsuk Choi, Eun-Ji Choi, Han-Seung Park, Hyunkyung Park, Joon Young Hur, Jisoo Jung, Seungah Cha, Young-Shin Lee, Mijin Jeon, Ji Min Woo, Young-A Kang, Hyeran Kang

Blood (2025) 146 (Supplement 1): 7819.

https://doi.org/10.1182/blood-2025-7819

Published: 2025

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Blood (2025) 146 (Supplement 1): 907.

https://doi.org/10.1182/blood-2025-907

Published: 2025

Journal Articles

Comprehensive analysis of long-term outcomes in adult patients with acute lymphoblastic leukemia who received allogeneic stem cell transplantation: Real-world data of the Korean society of blood and marrow transplantation registry

Dong Won Baek, Je-Hwan Lee, Joon Seong Park, Deok-Hwan Yang, Ji Hyun Lee, Yeung-Chul Mun, Ho Sup Lee, Ka-Won Kang, Seong Kyu Park, Chul Jung, Soo-Mee Bang, Joon Ho Moon

Blood (2025) 146 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2025-4286

Published: 2025

Journal Articles

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

Seung Kwon Koh, Hyojin Kim, Bohwa Han, Hantae Jo, Junsang Doh, Jeehun Park, Minh Ha Nguyen, Hyun-Young Kim, Haneul Kim, Seung-Hwan Lee, Chan Hyuk Kim, Duck Cho

Blood (2025) 145 (9): 956–969.

https://doi.org/10.1182/blood.2024025673

Published: 2025

Includes: Supplemental data

Journal Articles

Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

Hawk Kim, Jae-Sook Ahn, Sung-Hyun Kim, Ho-Young Yhim, Sung-Nam Lim, Yoo Jin Lee, Jeong-Ok Lee, Eun-Ji Choi, Je-Hwan Lee

Blood (2024) 144 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2024-201404

Published: 2024

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Alexander Röth, Guangsheng He, Andres Brodsky, Chatree Chai-Adisaksopha, Narcisa Sonia Comia, Anna Gaya, Martin Höglund, Richard J. Kelly, Ahlam Naila Kori, Je-Hwan Lee, Naoshi Obara, Antonio M Risitano, Anita Appius, Leigh Beveridge, Brittany Gentile, Zilu Zhang, Bing Han, Sasha Sreckovic

Blood (2024) 144 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2024-208072

Published: 2024

Journal Articles

The Optimal Busulfan Dose of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Younger Patients with Acute Myeloid Leukemia

Yunsuk Choi, Eun-Ji Choi, Han-Seung Park, Jung-Hee Lee, Kyoo-Hyung Lee, Young-Shin Lee, Young-A Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je-Hwan Lee

Blood (2023) 142 (Supplement 1): 6991.

https://doi.org/10.1182/blood-2023-189327

Published: 2023

Journal Articles

Predicting Disease Progression from Idiopathic Cytopenia of Undetermined Significance to Myeloid Malignancies Using a Machine Learning-Based Approach

Eun-Ji Choi, Jiye Han, Tae Joon Jun, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo Hyung Lee, Young-Hak Kim, Je-Hwan Lee

Blood (2023) 142 (Supplement 1): 7154.

https://doi.org/10.1182/blood-2023-188822

Published: 2023

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

Antileukemic Activity of Ypn-005, a CDK7 Inhibitor, Inducing Apoptosis through c-MYC and FLT3 Suppression in Acute Myeloid Leukemia

Bon-Kwan Koo, Je-Hwan Lee, Eun-Ji Choi, Eun-Hye Hur, Ju Hyun Moon, Ji Yun Kim, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo Hyung Lee, Jinhwan Kim

Blood (2022) 140 (Supplement 1): 8803–8804.

https://doi.org/10.1182/blood-2022-168726

Published: 2022

Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2022) 140 (Supplement 1): 3365–3366.

https://doi.org/10.1182/blood-2022-165000

Published: 2022

Journal Articles

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Blood (2022) 140 (Supplement 1): 6592–6593.

https://doi.org/10.1182/blood-2022-171149

Published: 2022

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Higher-Risk Myelodysplastic Syndrome

Eun-Ji Choi, Han-Seung Park, Jung-Hee Lee, Kyoo Hyung Lee, Youngshin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je-Hwan Lee

Blood (2021) 138 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2021-150389

Published: 2021

Journal Articles

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Dong Won Baek, Sr., Joon Ho Moon, Jae-Sook Ahn, Seong Kyu Park, Ik Chan Song, Ho-Sup Lee, Won Sik Lee, Jong Ho Won, Hong Ghi Lee, June-Won Cheong, Yeung-Chul Mun, Chul W. Jung, Je-Hwan Lee, Hyeoung-Joon Kim, Sang Kyun Sohn

Blood (2021) 138 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2021-154470

Published: 2021

Journal Articles

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Anish Puliyayil, Joseph Clarey, Jeejin Im, Ky-Youb Nam, Kyu-Tae Kim, June H-J. Han, Jeong-Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2021) 138 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2021-149395

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Impact of pre-transplant cytoreductive therapy on post-transplant outcomes in patients with myelodysplastic syndromes with excess of blasts: A retrospective analysis

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Comprehensive analysis of long-term outcomes in adult patients with acute lymphoblastic leukemia who received allogeneic stem cell transplantation: Real-world data of the Korean society of blood and marrow transplantation registry

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

The Optimal Busulfan Dose of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Younger Patients with Acute Myeloid Leukemia

Predicting Disease Progression from Idiopathic Cytopenia of Undetermined Significance to Myeloid Malignancies Using a Machine Learning-Based Approach

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Antileukemic Activity of Ypn-005, a CDK7 Inhibitor, Inducing Apoptosis through c-MYC and FLT3 Suppression in Acute Myeloid Leukemia

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Higher-Risk Myelodysplastic Syndrome

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only